Cargando…

Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response

PURPOSE: Long-term effects on patient health-related quality of life (HRQoL) after direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) are unknown. We assessed the impact of DAA-mediated HCV clearance on HRQoL from DAA initiation to 1 year after confirmed sustained virological respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyasaka, Akio, Yoshida, Yuichi, Suzuki, Akiko, Takikawa, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602143/ https://www.ncbi.nlm.nih.gov/pubmed/34013404 http://dx.doi.org/10.1007/s11136-021-02874-6

Ejemplares similares

Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review
por: Miyasaka, Akio, et al.
Publicado: (2020)

A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
por: Miyasaka, Akio, et al.
Publicado: (2021)

Fatal acute hepatic failure in a family infected with the hepatitis A virus subgenotype IB: A case report
por: Yoshida, Yuichi, et al.
Publicado: (2017)

Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination
por: Miyasaka, Akio, et al.
Publicado: (2019)

Hepatitis B Surface Antibody Titers at One and Two Years after Hepatitis B Virus Vaccination in Healthy Young Japanese Adults
por: Kakisaka, Keisuke, et al.
Publicado: (2019)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
por: Han, Sung Yong, et al.
Publicado: (2021)

Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C
por: Siddique, Muhammad Shoaib, et al.
Publicado: (2017)

Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
por: Meissner, Eric G., et al.
Publicado: (2014)

Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection
por: Miyasaka, Akio, et al.
Publicado: (2022)

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients
por: Zaki, Seham Mahrous, et al.
Publicado: (2022)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1
por: Miyasaka, Akio, et al.
Publicado: (2018)

Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response
por: van Wezel, E M, et al.
Publicado: (2019)

Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
por: Havens, Joshua P., et al.
Publicado: (2020)

Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
por: Eckardt, Paula, et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
por: Manabe, Takushi, et al.
Publicado: (2022)

A 55-Year-Old Japanese Man with Multiple Sclerosis Diagnosed with Disseminated Tuberculosis Identified by Liver Function Abnormalities: A Case Report
por: Miyasaka, Akio, et al.
Publicado: (2021)

A 51-Year-Old Woman with Drug-Induced Hypersensitivity Syndrome Associated with Carbamazepine, Reactivation of Human Herpesvirus 6, and Acute Liver Failure: A Case Report
por: Miyasaka, Akio, et al.
Publicado: (2021)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir
por: Mawatari, Seiichi, et al.
Publicado: (2018)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits
por: Smith-Palmer, Jayne, et al.
Publicado: (2015)

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study
por: Mekky, Mohamed A, et al.
Publicado: (2019)

Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort
por: Steinebrunner, Niels, et al.
Publicado: (2015)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir
por: Ismail, Elshahat Ibrahem, et al.
Publicado: (2018)

Durability of Sustained Virologic Response in Chronic Hepatitis C
por: Uyanikoglu, Ahmet, et al.
Publicado: (2013)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
por: Noureddin, Mazen, et al.
Publicado: (2018)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting
por: Han, Qunying, et al.
Publicado: (2019)

Initial results of efficacy and safety of Sofosbuvir among Pakistani Population: A real life trial - Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS)
por: Azam, Zahid, et al.
Publicado: (2017)

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study
por: Tada, Toshifumi, et al.
Publicado: (2020)

Predictors of early and sustained virological response of viral hepatitis C
por: Ghenea, Alice Elena, et al.
Publicado: (2020)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir
por: Wang, Xiao-Xiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nrp66j60jksm7m9vnfg05rreds